Ignite Creation Date:
2024-05-06 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06140836
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2023-11-15
Brief Title:
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor TKI-naïve ROS1-positive Non-Small Cell Lung Cancer NSCLC TRIDENT-3
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb